Please enable JavaScript.
Coggle requires JavaScript to display documents.
Finerenone - Coggle Diagram
Finerenone
Dosage
-
-
-
-
Increase dose after 4 weeks to the target dose of 20 mg qDay based on eGFR and serum potassium thresholds
Indication
-
indicated to reduce the risk of sustained eGFR decline, end stage kidney disease,
cardiovascular death, non-fatal myocardial infarction, and
hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D).
MOA
Finerenone is a nonsteroidal, selective antagonist of the mineralocorticoid receptor (MR), which is activated by aldosterone and cortisol and regulates gene transcription.
Finerenone blocks MR mediated sodium reabsorption and MR overactivation in both epithelial (e.g., kidney) and nonepithelial (e.g., heart, and blood vessels) tissues.
-
Finerenone has a high potency and selectivity for the MR and has no relevant affinity for androgen, progesterone, estrogen, and glucocorticoid receptors.
ADR
Adverse reactions occurring in ≥ 1% of patients on Finerenone are hyperkalemia, hypotension, and hyponatremia
-